-- New Porous Iteration of Anatomic Keeled
Tibia Designed to Deliver Stable Initial and Biological Fixation
Together with the Clinically Proven Benefits of the
Persona Knee System --
WARSAW,
Ind., Nov. 21, 2022 /PRNewswire/ -- Zimmer
Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical
technology leader, today announced U.S. Food and Drug
Administration (FDA) 510(k) clearance for the Persona®
OsseoTi® Keel Tibia for cementless knee replacement.
Persona OsseoTi is the latest addition to the clinically proven
Persona Knee System, and features a new porous version of the
Persona anatomic tibia with Zimmer Biomet's OsseoTi Porous
Metal Technology, which uses anatomical data in combination with 3D
printing technology to build a structure that directly mimics the
architecture of human cancellous – or spongey – bone. This material
is combined with a keeled design to deliver stable initial and
biological fixation.
![(PRNewsfoto/Zimmer Biomet Holdings, Inc.) (PRNewsfoto/Zimmer Biomet Holdings, Inc.)](https://mma.prnewswire.com/media/1603977/Zimmer_Biomet_Holdings_Logo.jpg)
"With an increasing number of surgeons opting for cementless
procedures for their patients, we are excited to expand our
market-leading Persona Knee portfolio with the Persona OsseoTi Keel
Tibia, a versatile and surgeon-centered solution for performing a
cementless total knee replacement," said Ivan Tornos, Chief
Operating Officer at Zimmer Biomet. "Adding the Persona OsseoTi
Keel Tibia to our well-established and clinically proven Persona
Knee System allows surgeons to better address the needs of their
patients with a comprehensive single system solution for a
cementless or cemented application. We're proud to close out the
year with another advancement in our portfolio, thanks to the
strong execution of our team members and our commitment to fueling
growth with innovation."
Key features of Persona OsseoTi include an anatomic tibia for
less micromotion and optimal bone coveragei and 3D
printed, porous OsseoTi technology for biological
fixation. The Persona OsseoTi Keel Tibia is also complemented with
a new cemented implant option to enable seamless versatility for
the surgeon during the procedure.
"The predicted growth in the prevalence of arthritis in younger,
active patients has made cementless total knee arthroplasty an
increasingly essential option for surgeons," said Charles Lawrie, M.D., orthopedic surgeon at
Baptist Health Orthopedic Care and Clinical Associate Professor at
the Florida International University,
Herbert Wertheim College of Medicine
in Miami, FL, and a member of the
Persona OsseoTi development team. "In addition to the spike-keel
design, the Persona OsseoTi Keel Tibia offers the added convenience
of a new cemented option with the same bone prep as the cementless
option so that surgeons can make an intraoperative decision between
a cementless or cemented approach based on bone quality and the
unique needs of their patient."
For more information about the Persona OsseoTi Keel Tibia, visit
https://www.zimmerbiomet.com/en/products-and-solutions/specialties/knee/persona-osseotikeeltibia.html.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader
with a comprehensive portfolio designed to maximize mobility and
improve health. We seamlessly transform the patient experience
through our innovative products and suite of integrated digital and
robotic technologies that leverage data, data analytics and
artificial intelligence.
With 90+ years of trusted leadership and proven expertise,
Zimmer Biomet is positioned to deliver the highest quality
solutions to patients and providers. Our legacy continues to
come to life today through our progressive culture of evolution and
innovation.
For more information about our product portfolio, our operations
in 25+ countries and sales in 100+ countries or about joining our
team, visit www.zimmerbiomet.com or follow Zimmer Biomet
on Twitter at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding
Forward-Looking Statements
This news release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include,
but are not limited to, statements concerning Zimmer Biomet's
expectations, plans, prospects, and product and service offerings,
including new product launches and potential clinical successes.
Such statements are based upon the current beliefs and expectations
of management and are subject to significant risks, uncertainties
and changes in circumstances that could cause actual outcomes and
results to differ materially. For a list and description of some of
such risks and uncertainties, see Zimmer Biomet's periodic reports
filed with the U.S. Securities and Exchange
Commission (SEC). These factors should not be construed as
exhaustive and should be read in conjunction with the other
cautionary statements that are included in Zimmer Biomet's filings
with the SEC. Forward-looking statements speak only as of the date
they are made, and Zimmer Biomet disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
Readers of this news release are cautioned not to rely on these
forward-looking statements, since there can be no assurance that
these forward-looking statements will prove to be accurate. This
cautionary statement is applicable to all forward-looking
statements contained in this news release.
i Data on file with Zimmer Biomet: The
Persona® OsseoTi® Keel Tibia Provides Strong
Initial Fixation. Nov. 2022.
4027.1-GLBL-en
345 E. Main St.
Warsaw, IN 46580
www.zimmerbiomet.com
Media
|
|
Investors
|
Meredith
Weissman
|
|
Keri Mattox
|
703-346-3127
|
|
215-275-2431
|
meredith.weissman@zimmerbiomet.com
|
|
keri.mattox@zimmerbiomet.com
|
|
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-expands-persona-knee-system-portfolio-with-fda-clearance-of-persona-osseoti-keel-tibia-for-cementless-knee-replacement-301683440.html
SOURCE Zimmer Biomet Holdings, Inc.